Epidermal growth factor receptor is expressed and active in a subset of acute myeloid leukemia

The epidermal growth factor receptor (EGFR) inhibitor erlotinib has been shown to induce complete remission of acute myeloid leukemia (AML) in two patients with concurrent lung cancer and raised attention for a role of EGFR in AML whereas a recent phase II clinical study with gefitinib in AML demons...

Full description

Saved in:
Bibliographic Details
Published in:Journal of hematology and oncology 2016-08, Vol.9 (1), p.64-64, Article 64
Main Authors: Mahmud, Hasan, Kornblau, Steven M, Ter Elst, Arja, Scherpen, Frank J G, Qiu, Yi Hua, Coombes, Kevin R, de Bont, Eveline S J M
Format: Article
Language:English
Subjects:
Adolescent
Adult
AML
Analysis
Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
Bioinformatics
Bone marrow
Cell cycle
Child
Cluster Analysis
Consent
Design
EGFR
Epidermal growth factor
Female
Gene expression
Genetic aspects
Hematology
Humans
Influence
Kinases
Kinome
Letter to the Editor
Leukemia
Leukemia, Myeloid, Acute - enzymology
Leukemia, Myeloid, Acute - pathology
Lung cancer
Male
Middle Aged
Oncology
Patients
Pediatrics
Peptides
Phosphorylation
Protein expression
Protein Kinase Inhibitors - pharmacology
Protein Kinase Inhibitors - therapeutic use
Proteins
Receptor, Epidermal Growth Factor - analysis
Receptor, Epidermal Growth Factor - antagonists & inhibitors
Receptor, Epidermal Growth Factor - metabolism
RPPA
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The epidermal growth factor receptor (EGFR) inhibitor erlotinib has been shown to induce complete remission of acute myeloid leukemia (AML) in two patients with concurrent lung cancer and raised attention for a role of EGFR in AML whereas a recent phase II clinical study with gefitinib in AML demonstrated a negative result on the outcome. However, from several studies, EGFR expression in AML is poorly defined and the role of EGFR in AML remains unclear. Herein, we report the results of EGFR expression in AML of large cohorts of adult and pediatric AML patients with the data of total protein and phosphorylation levels of EGFR. Our data conclude that there is the expression of EGFR at the protein level in a subset of AML, which was identified to be functionally active in ~15 % of AML patients. This suggests that future studies need to be conducted with a subset of AML patients characterized by high EGFR expression.
ISSN:1756-8722
1756-8722
DOI:10.1186/s13045-016-0294-x